Matching the Modality to the Disease: What Cell Therapy Type is Best for Which Indication?

Time: 9:00 am
day: Pre-Conference Day


As B cells are crucial to the pathogenesis of many autoimmune diseases, CD19 makes an attractive target because its expression is limited to those of a B-cell lineage. Additionally, the field has commonly developed therapies to treat indications such as lupus, multiple sclerosis, rheumatoid arthritis, and type 1 diabetes. But, what’s next for the field? What new targets and indications are on the horizon?

Through a variety of presentations and group discussions, this workshop will:

  • Discuss the advantages and disadvantages of CAR-T and Tregs: how do we leverage this knowledge to effectively treat a variety of indications?
  • Explore recent advances in antigen discovery: what antigens can we target beyond CD19?
  • Discuss the next big autoimmune indication: with initial success displayed in lupus, what’s next on the horizon?